Tempest Reports Year End 2024 Financial Results and Provides Business Update
• Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcinoma […]
Joseph Nigro Appointed to Eos Energy Enterprises Board of Directors
EDISON, N.J., March 27, 2025 (GLOBE NEWSWIRE) — Eos Energy Enterprises, Inc. (NASDAQ: EOSE) (“Eos” or the “Company”), America’s leading […]
Acuity Inc. Declares Quarterly Dividend
Atlanta, March 27, 2025 (GLOBE NEWSWIRE) — Acuity Inc. (NYSE: AYI) will pay a quarterly dividend of 17 cents per share. […]
INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update
BOCA RATON, Fla., March 27, 2025 (GLOBE NEWSWIRE) — INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology […]
Lifecore Biomedical to Report Financial Results for Third Quarter of Fiscal 2025 on April 3, 2025
CHASKA, Minn., March 27, 2025 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and […]
Wintrust Names New Leader for Brand, Engagement, and Impact
ROSEMONT, Ill., March 27, 2025 (GLOBE NEWSWIRE) — Wintrust Financial Corporation (Nasdaq: WTFC) today announced Amy Yuhn has been named […]
Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro™
Seventh GPO Agreement Signed Since EluPro’s Launch SILVER SPRING, Md., March 27, 2025 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq: ELUT) […]
Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly
SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the European Medicines Agency […]
Global Water Completes $32.2 Million Public Offering of Common Stock; Underwriters Exercise Full Over-Allotment Option
PHOENIX, March 27, 2025 (GLOBE NEWSWIRE) — Global Water Resources, Inc. (NASDAQ: GWRS), a pure- play water resource management company, […]
CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update
– Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in two of four […]
